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Health-related quality of life of patients with Generalized Anxiety Disorder 
 
Abstract 
Aims: To analyze the health-related quality of life of patients with Generalized Anxiety 
Disorder (GAD), with respect to the population at large and to a control group. The 
following goals are addressed: 1.- To determine what, if any, differences exist between 
the health status of patients diagnosed with GAD, the population in general and a group 
of control patients; 2.- To analyze the relation between the variables age, sex, and health 
status (as assessed by the patient’s GP) measured on the Hamilton anxiety scale, with 
the quality of life of the GAD patients and of the control group; 3.- To determine 
whether the variables age, sex, Hamilton scale values and index of quality of life 
influence the annual cost caused by the illness; 4.- To determine whether there are any 
differences in the evaluation of the same health status made by GAD patients and by the 
general population. This study forms part of a broader-ranging one (the ANCORA 
Study) set up to analyze Generalized Anxiety Disorder (GAD) and the costs and other 
burdens provoked by this illness in Spain. 
Material and Methods: Regression models were used to obtain the EQ-5D index of 
health state (EQindex) and to analyze the above-mentioned variables. The data on patients 
and on the costs of the illness are those registered in the ANCORA study.  
Results: The patients with GAD present a self-perceived level of health (EQ-5D) that is 
conspicuously below that corresponding to the general population, especially in three of 
the dimensions, namely usual activities, pain/discomfort and anxiety/depression. The 
mean value of the health index (EQindex) is ten points below that of the general 
population and that of the control group. Age was found to be negatively related to the 
health variables, as was a higher score on the Hamilton scale. For the group of patients 
with GAD, a worse perceived health state and a higher score on the Hamilton scale were 
associated with higher costs, although in the latter case the explicative power of the 
model is weak. Finally, the GAD patients assessed their health status more negatively 
than did the general population, with a visual analogue scale (VAS) result that was four 
points lower than that made by the general population. 
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Introduction 
GAD is an anxiety disorder that is clearly specified within disease classification 
systems. Both in the DSM-IV classification system (APA, 2000) and in CIE-10 (WHO, 
1992), there is an explicit separation between the generalized anxiety syndrome (GAD) 
and other syndromes of anxiety or depression (Mahe and Balogh, 2000). 
It has been estimated that the lifetime prevalence for persons diagnosed with GAD is 
5.1% (DSM-IV), and in accordance with the classification criterion used in Europe, it is 
6.5% (CIE-10) (ADAA, 2004). In studies of the general population, the prevalence of 
GAD ranges from 5-7% (Lobo and Campos, 1997). 
Over half of the patients with anxiety disorders are believed to visit primary healthcare 
clinics for treatment. Of these patients, approximately 8% are diagnosed with GAD, 
which means this is the most prevalent of all anxiety disorders (Wittchen, 2002). 
In Spain, the prevalence of GAD reported in studies of primary healthcare attention 
ranges from 4.5% (Zaragoza study, 1993, in Lobo and Campos, 1997), to 7.3% 
(Chocrón et al., 1995) to 7.9% (Goldberg and Lecrubier, 1995). 
A combination of genetic, biological, socioeconomic and employment-related factors 
may influence the appearance of GAD. Although its exact cause has yet to be 
determined, some population groups are at higher risk; for example, Afro-American 
women aged under 30 years present a higher probability of suffering this illness 
(Horwath and Weissman, 1995, in Cano Vindel, 2005). The prevalence among women 
aged over 45 years is 8-10%. Furthermore, GAD is the anxiety disorder that is most 
frequently suffered among the population aged over 65 years (Andlin-Sobocki and 
Wittchen, 2005).  
One of the effects of GAD is its impact on patients’ quality of life. Even after adjusting 
for age, sex and the presence of other pathologies, such as severe depression, there is 
clearly a reduction in the quality of life of persons affected by GAD, and in 
consequence, a gradual loss of psychosocial functionality (Albarracín et al., 2007; 
Hoffman, Dukes and Wittchen, 2008, Wittchen et al., 2000). 
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The present study forms part of a wider-ranging one, termed the ANCORA study, 
aimed at analyzing Generalized Anxiety Disorder (GAD), together with the cost and 
other burdens caused by the illness in Spain. The goals of the ANCORA study include 
evaluating the cost and other burdens of the illness with respect to patients’ health 
status, as determined on self-perceived health scales. This study employs two 
instruments for assessing health-related quality of life, namely SF-36 and EQ-5D. The 
first of these is a profile with eight dimensions related to health status, measured in 
terms of functional state and emotional wellbeing. The dimensions, however, are not 
combined to form an index (Ware et al., 1993, Alonso, Prieto and Antó, 1995). 
EQ-5D, which was developed by the EuroQoL group, is also a generic, standardized 
instrument, which was created to describe and assess the health-related quality of life 
(Brooks, 1996). Its aim is to produce a cardinal index of health, which has considerable 
potential for use in economic evaluation and as a synthetic measure of the health of 
individuals and of population groups. At present, the index created by Dolan (1997) is 
increasingly employed in the evaluation of healthcare procedures. This index has been 
recommended for use in cost-utility analysis of healthcare technologies by the National 
Institute for Clinical Excellence (NICE), to guide the decisions taken within the British 
National Health Service (Roberts and Dolan, 2004). 
In the present study, an analysis is made of the health-related quality of life of patients 
with GAD, in relation both to the general population and to a control group, and seeks 
to achieve the following: 1.- To determine what, if any, differences exist between the 
health status of patients diagnosed with GAD, the population in general and a group of 
control patients; 2.- To analyze the relation between the variables age, sex, and health 
status (as assessed by the patient’s GP) measured on the Hamilton anxiety scale, with 
the quality of life of the GAD patients and of the control group; 3.- To determine 
whether the variables age, sex, Hamilton scale and index of quality of life influence the 
annual cost caused by the illness; 4.- To determine whether there are any differences in 
the evaluation of the same health status made by GAD patients and by the population in 
general. Econometric regression models are used to derive an EQ-5D health index and 
also to analyze the above-mentioned variables. When a priori information is available, 
Bayesian statistics are used. The data on the patients and on the costs of the illness are 
those obtained in the ANCORA study. 
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Material and Methods 
The ANCORA project is an observational, retrospective, longitudinal and multicentre 
study of Generalized Anxiety Disorder (GAD), and of its costs and other burdens, 
carried out in Spain with the participation of doctors at primary healthcare clinics. The 
criteria for inclusion in the study were that the patients should be out-patients, of either 
sex, aged over 18 years, diagnosed with Generalized Anxiety Disorder (codes CIE-9: 
300.02 and CIE-10: F41.1) and with data reflecting a clinical history of at least twelve 
months. The patient should give written consent to participate in the study and be 
capable of reading, understanding and completing health-related questionnaires drafted 
in Spanish. Criteria for exclusion, as well as not satisfying those for inclusion, were the 
presence of severe illness that might interfere with the patient’s ability to complete the 
questionnaire, or of mental handicap that might interfere with the patient’s capacity to 
remember the previous use made of healthcare resources, or to complete the 
questionnaire. 
 
Measuring Health-Related Quality of Life  
Quality of life was measured using EQ-5D, an instrument that was designed as a self-
assessed questionnaire, comprised of two parts. 
Part 1 obtains a description of the individual’s health status, via five dimensions: 
mobility (MO), self-care (SC), usual activities (UA), pain/discomfort (PD) and 
anxiety/depression (AD). Each of these dimensions is then sub-divided into three levels: 
no health problems (1), moderate health problems (2) and extreme health problems (3). 
Each interviewee identified a level for each of the five dimensions, and so their health 
status was described by five digits, with values from 1 to 3, such that a health state of 
11111 was considered a priori to be the best possible, and 33333 would represent the 
worst possible one. The combination of these levels defines a total of 243 (35) states of 
health. 
In Part 2, the interviewee was asked to assess his/her health status on the basis of a 
vertical visual analogue scale (VAS), like that of a thermometer, where “the best health 
state imaginable” is given a value of 100, and “the worst health state imaginable” is 
given a value of 0. 
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From these EVA scores, values may be obtained for the 243 health states reflected by 
the EQ-5D measure. Dolan (1996), a pioneer in the field of indexes of health status, 
showed there to be a linear relation between the value of an index and that of the 
dummy variables corresponding to the different levels of each of the dimensions of the 
EQ-5D instrument. Moreover, to test the hypothesis that the value of the index 
decreases when one of these dimensions is located at the level associated with “extreme 
health problems”, the latter author proposed that an additional dummy variable (N3) 
should be incorporated, to be given a value of 1 if any dimension was located at level 3. 
Using coefficients to establish relations between the index and the different dimensions 
makes it possible to interpolate values of health states that were not observed directly, 
and thus to obtain the values of the 243 EQ-5D states. This functional relation is 
employed throughout the present study. The index values used are based on data 
obtained from the Catalonian Health Survey (ESCA), carried out in 2002 and in 2006. 
 
Models utilized 
 Obtaining the EQ-5D health index (EQindex) 
An index for the general population (EQindex) is obtained by means of a model similar to 
that used by Dolan (1996), using the following expression: 
 
Y i /100 = β0 + β1 MO2i + β2 SC2i + β3 UA2i + β4 PD2i + β5 AD2i + β6 MO3i +  
+ β7 SC3i + β8 UA3i + β9 PD3i + β10 AD3i + β11 N3i  
         Model 1 
VASscore i ~ N(Y i, τ)  τ ~ G (a , b) 
βj ~ N(βj, Ωjxj),  j=0,…,11        
 
The variables used for this model take the following values: 
MO2, SC2, UA2, PD2, AD2 if the response has a value of 2, then it is 1; otherwise = 0. 
MO3, SC3, UA3, PD3, AD3 if the response has a value of 3, then it is 1; otherwise = 0. 
N3 if the response has a value of 3 in any of the dimensions, then it is 1; otherwise = 0. 
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Once the coefficients of interest are known, the index value for a health state is calculated 
from the mean value of the dependent variable explained for that health state (EQindex i). 
Between-sample comparison of the health status index  
We now obtain the index value for each one of the individuals in the general population 
sample and also for the persons diagnosed with GAD. This value represents one of the 
243 possible health states. The following functional form is used to analyze the 
differences in the index: 
 
Y i = α0 POPi + α1 GADi  
         Model 2 
EQindex  i ~ N(Y i, τ)  τ ~ G (a , b) 
αj ~ N(αj, Ωjxj),  j=0,1      
 
where  POP = 1 if the person belongs to the general population; otherwise, 0. 
 GAD = 1 if the person belongs to the group diagnosed with GAD; otherwise 0. 
We also calculated the differences in the index between the persons diagnosed with 
GAD and the control group used in the ANCORA study, in accordance with the 
following model: 
 
EQindex i = β1 CONTi + β2 GAD + ui  
         Model 3 
 
where  CONT = 1 if the person belongs to the control group; otherwise, 0. 
 GAD = 1 if the person belongs to the group diagnosed with GAD; otherwise 0. 
 
Relation between health state assessment and the Hamilton score 
The relation between each of the variables age, sex and Hamilton scale score for anxiety 
with the quality of life of patients with GAD and of those in the control group, 
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measured using the variables EVAscore i  and EQindex  i., is analyzed by means of the 
following models: 
 
Model 4.1: the dependent variable is the VAS 
VAS score i = β0 + β1 Sexi + β2 Agei + β3 Hamtoti + ui 
         Model 4.1 
Model 4.2: the dependent variable is EQindex i,  the index obtained in Model 1 
EQindex i = β0 + β1 Sexi + β2 Agei + β3 Hamtoti + ui 
         Model 4.2 
where  Sex = 1 if the person is female; otherwise, = 0. 
 Age in years 
 Hamtot measured from the Hamilton scale values 
 
Variables that influence the cost of the illness 
We wish to determine whether the variables age, sex, Hamilton scale values and index 
of quality of life influence the logarithmic transform of the annual cost of the illness 
(AnnCost), using the following functional form: 
 
Log(AnnCost i ) = β0 + β1 Sexi + β2 Agei + β3 Hamtoti + β3 EQindex i  +ui 
         Model 5 
 
Differences between patients and the general population in assessing the same health 
status 
For the patients diagnosed with GAD, we analyzed the difference between VAS and 
EQindex, which represents the value assigned by the patient to his/her health status on the 
VAS less that assigned by the general population to the same health status, as described 
by the five dimensions of the EQ-5D. This was performed on a patient-by-patient basis, 
and we present descriptive statistics of the variable resulting from the variation between 
the evaluations (∆Val): 
∆Val i = VASi – EQindex i  
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Calculation methodology 
The computations and simulations made for Models 1 and 2 were carried out by 
Bayesian statistics, using Gibbs sampling and Metropolis-Hasting algorithms, which 
constitute the two basic approaches used in the Markov Chain Monte Carlo 
methodology (Gilks et al., 1996). These algorithms were applied by means of 
WinBUGS 1.4 statistical software (Spiegelhalter et al., 2003). For the simulations, a 
total of 100000 iterations were carried out, after a burn-in run of 10000, with a few 
minutes being required for the simulation of each model. 
In addition, a non-informative a priori distribution was used, except in the calculation 
performed to obtain the EQindex variable. In estimating the a posteriori distributions of 
the mean and the variance in the parameters, in order to obtain the value of the index, 
the a posteriori data from the ESCA 2002 sample was incorporated as a priori 
information for the ESCA 2006 sample. 
Models 3, 4-1, 4-2 and 5 were calculated using the ordinary least squares estimation 
procedure, with Eviews 5 software. 
 
Data 
The EQindex of health was obtained using the Catalonian Health Surveys published by 
the Health Ministry of the Generalitat (Catalonian Regional Government) for the years 
2002 and 2006 (ESCA 2002 and ESCA 2006). These surveys correspond to the non-
institutionalized population of Catalonia, with sample sizes of 8,089 and 16,164, 
respectively.  
Other analyses were based on the data taken from the ANCORA study, using a sample 
of patients with GAD (N= 456) and a control group (N= 74) who were treated during 
2006 at 134 primary healthcare clinics (Rovira et al., 2008; Albarracín et al., 2008). The 
samples were distributed by age, sex and geographic groups, in accordance with the 
populational weight of each Autonomous Community (Region) in Spain. The data were 
obtained by means of two questionnaires filled in by the patient and by his/her GP, 
respectively. 
The questionnaire filled in by the GP contained two blocks of questions. The first of 
these referred to sociodemographic data, comorbidity, sick leave (including sick leave 
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attributable to GAD), the course of the illness, medication prescribed (for GAD and for 
any other health problem), and also questions aimed at determining the doctor’s own 
view of the severity of the patient’s illness. The second block referred to data for 
obtaining an evaluation on the Hamilton Anxiety Rating Scale. 
The information provided by the patient was classified in five blocks. The first one was 
for personal data, information as to whether the patient had a carer/nursing help, the 
course of the illness, the medication being taken (and any side effects occurring). The 
following blocks corresponded to questionnaires on Sheehan’s syndrome, the EQ-5D 
index, the SF-36 index and the MOS sleep scale, respectively. 
 
Results 
The relevant sociodemographic characteristics for the patients included in this study are 
shown in Table 1. 
Table 1 
Sociodemographic characteristics of the GAD patients and of the controls 
 
 
 
 
 
 
 
 
 
 
N: 456 patients and 74 controls, of whom: 3 patients with GAD and 1 control did 
not state their sex; 12 patients with GAD and 3 controls did not state their age. 
 
From the replies to the EQ-5D survey, we obtained data on 518 participants for the first 
part of the questionnaire, distributed as 444 cases of GAD and 74 controls. Figure 1 
shows, as percentages, the replies concerning the five dimensions that constitute the 
EQ-5D measure, among the general population and among patients with GAD, 
Patients with GAD  Controls Characteristics 
N  %  N %  
Sex     
Male 105 23.18% 42 57.53% 
Female 348 76.82% 31 42.47% 
Age (years)     
18 – 34 122 27.5% 17 23.9% 
35 – 64 201 45.3% 37 52.1% 
>= 65 121 27.3% 17 23.9% 
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illustrating the existence of marked differences between the variables usual activities, 
pain/discomfort and anxiety/depression. More than half of the patients located these 
dimensions between scores of 2 and 3. These differences are not so conspicuous for the 
variables mobility and self care. 
 
Figure 1 
EQ-5D dimensions for the general population and for GAD patients (%) 
MOBILITY
85.27%
14%
0.73%
80.18%
19.59%
0.23%
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
No problems Moderate problems Extreme problems
General population GAD patients
 
 
 SELF-CARE
94.43%
4.14% 1.41%
89.63%
10.37%
0.00%
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
No problems Moderate problems Extreme problems
General population GAD patients
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USUAL ACTIVITIES
88.42%
9.25%
2.32%
49.77% 47.70%
2.53%
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40.00%
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PAIN / DISCOMFORT
68.33%
25.49%
6.17%
31.80%
57.37%
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20.00%
40.00%
60.00%
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ANXIETY / DEPRESSION
81.65%
14.61%
3.73%
16.13%
66.13%
17.74%
0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
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General population GAD patients
 
 
 
 12 
Model 1 
The VAS responses were obtained from 404 participants distributed as 345 GAD 
patients and 59 controls. Table 2 shows the results for Model 1 concerning the values of 
the VAS/100 variable, the a posteriori distribution of the coefficients of interest (mean 
and standard deviation), and the Bayesian 95% probability intervals for the model, with 
the information obtained in the ESCA 2006 survey and using ESCA 2002 as an a priori 
source. 
Table 2 
Results of Model 1 for the values of the VAS/100 variable,  
the a posteriori distribution of the coefficients of interest (mean and standard 
deviation), and the Bayesian 95% probability intervals  
 
Model 1 (N = 24253) Associated Variables 
 mean (sd) 95% BI 
Constant 0.800(0.0012) (0.79,0.80) 
MO2 -0.088(0.0035) (-0.09,-0.08) 
SC2 -0.007(0.0057) (-0.02,0.00) 
UA2 -0.086(0.0043) (-0.09,-0.08) 
PD2 -0.111(0.0024) (-0.12,-0.11) 
AD2 -0.077(0.0029) (-0.08,-0.07) 
MO3 -0.124(0.0131) (-0.15,-0.10) 
SC3 -0.060(0.0115) (-0.08,-0.04) 
UA3 -0.146(0.0095) (-0.16,-0.13) 
PD3 -0.173(0.0070) (-0.19,-0.16) 
AD3 -0.156(0.0068) (-0.17,-0.14) 
N3 -0.001(0.0071) (-0.02,0.010) 
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The mean value of the parameters associated with the variables is negative, which 
means that the index is constructed in such a way that the 11111 state represents the 
highest value, while the parameters associated with level 3 (extreme health problems) 
lower the value of the index to a greater degree than do those associated with the level 2 
(moderate health problems) of the corresponding dimension. Therefore, the variable 
created from these results (EQindex) presents an order of values of health states that is 
free of inconsistencies, with a value of 80% corresponding to the 11111 state. 
 
Model 2 
Table 3 and Figure 2 show the results obtained by Model 2 for the EQindex, the a 
posteriori distribution of the coefficients of interest (mean and standard deviation) and 
the Bayesian 95% probability intervals for the general population and for patients with 
GAD. 
 
Table 3 
Results of Model 2 for the EQindex values, the a posteriori distribution of the 
coefficients of interest (mean and standard deviation) and the Bayesian 95% 
probability intervals 
 
 
 
 
The GAD patients presented a mean health status value that was 10 points below that of 
the general population, which illustrates the effect of GAD on the perceived health-
related quality of life. Figure 2 shows that the differences in terms of probability are 
substantial, as there is no overlap of the a posteriori distributions of the parameters.   
Model 2 (N = 24,687) Associated variables 
 mean (sd) 95% BI 
POP 73.70(0.0709) (73.56,73.84) 
GAD 63.46(0.5256) (62.43,64.48) 
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Figure 2 
A posteriori distributions of the parameters of interest in Model 2 
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Model 3 
Table 4 shows the results of Model 3 for the EQindex, the distribution of the coefficients 
of interest: the mean, the standard deviation and the level of significance (p-value) for 
the GAD patients and the controls. 
 
Table 4 
Results from Model 3 for the EQindex, the distribution of the coefficients of interest: 
mean, standard deviation and level of significance (p-value) 
Model 3 (N=506) 
Associated variables mean (sd) p-value 
CONT 76.25(1.231) (0.0000) 
GAD 63.46(0.501) (0.0000) 
R2 0.154 
Adjusted R2 0.153 
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The results obtained for the patients in the control group were similar to those for the 
general population in Model 2. 
 
Model 4 
Tables 5 and 6 show the relation between the variables age, sex and health status as 
assessed by the GP, measured on the Hamilton anxiety scale, and the quality of life of 
the GAD patients and the controls.  
 
Table 5 
Results of Model 4.1, where the dependent variable is the VAS score -  
mean, standard deviation and level of significance (p-value) 
 
 
 
 
 
 
 
 
 
 
 
GAD (N=333) CONTROL (N=57) Associated 
variables 
 
mean (sd) p-value mean (sd) p-value 
Constant 87.202(3.59) (0.000) 100.866(4.50) (0.000) 
Sex -2.464(2.09) (0.240) -0.0310(3.22) (0.992) 
Age -0.258(0.05) (0.000) -0.410(0.08) (0.000) 
Hamtot -0.721(0.09) (0.000) 0.331(0.26) (0.213) 
R2 0.220 
Adjusted R2  0.213 
R2  0.292 
Adjusted R2 0.252  
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Table 6 
Results of Model 4.2, where the dependent variable is the EQindex  
- mean, standard deviation and level of significance (p-value) 
 
 
The variable age has a negative and significantly non-zero relation with the health 
variables in both models, while the Hamilton scale data are only significant for the 
GAD patients in the two indexes. 
 
Model 5 
Table 7 shows the results, the mean, the standard deviation and level of significance (p-
value) of the parameters in which the dependent variable is the annual cost of the 
illness. 
 
 
 
 
 
 
 
GAD (N=418) CONTROL (N=68) Associated 
variables 
 
mean (sd) p-value mean (sd) p-value 
Constant 82.743(1.82) (0.000) 87.230(2.15) (0.000) 
Sex -1.490(1.08) (0.170) -1.960(1.38) (0.161) 
Age -0.159(0.02) (0.000) -0.215(0.04) (0.000) 
Hamtot -0.515(0.04) (0.000) -0.003(0.12) (0.979) 
R2 0.317 
Adjusted R2 0.285  
R2 0.286 
Adjusted R2 0.281 
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Table 7 
Results of Model 5. Mean, standard deviation and level of significance (p-value) of 
the parameters in which the dependent variable is the annual cost of the illness 
 
 
For the GAD patients, a poorer health status (as represented by a lower health state 
index) was associated with higher costs derived from the illness and a higher score on 
the Hamilton scale, at a higher cost. Nevertheless, the explicative power of the model is 
slight. 
 
Are there differences between the patients’ own assessment and that of the general 
population regarding their health status? 
The differences between the assessments of the same health status by GAD patients and 
by the general population were determined from the differences between the VAS 
scores and the mean values obtained for each health state in the EQindex i:  
∆Val i = VASi – EQindex i  
The results show that the GAD patients assessed their own health status an average of 
4.328 points (standard deviation 15.18) lower than did the general population, on the 
health status index (Figure 3). 
GAD (N=415) CONTROL (N=64) Associated 
variables 
 
mean (sd) p-value mean (sd) p-value 
Constant 9.672(0.65) (0.000) 9.150(3.68) (0.0159) 
Sex -0.370(0.16) (0.021) -1.174(0.47) (0.0157) 
Age -0.015(0.00) (0.000) -0.000(0.01) (0.9911) 
Hamtot 0.035(0.00) (0.000) -0.103(0.04) (0.0174) 
EQind -0.023(0.00) (0.001) -0.027(0.04) (0.5087) 
R2 0.132 
Adjusted R2 0.124 
R2 0.159 
Adjusted R2 0.102  
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Figure 3 
Health states assessment by GAD patients, compared to that made for the same 
health states by the general population  
 
 
 
Discussion 
One of the components of the burden imposed by illness is its effect on the health-related 
quality of life. The present study shows that the GAD patients in the sample have a self-
perceived health status (EQ-5D) that is markedly lower than that of the general population, 
especially in three of its dimensions – usual activities, pain/discomfort and 
anxiety/depression. The patients’ age was negatively related to both the health variables 
and to higher scores on the Hamilton scale (i.e., a worse health status, in the GP’s opinion). 
Our results are consistent with those reported in the, as yet, few published studies on the 
effects of GAD on health-related quality of life. The difficulty of isolating the specific 
effects of GAD, due to the presence of comorbidity, accounts for the scant number of 
studies made in this respect, but those that have appeared confirm that GAD has an 
important negative effect on the quality of life (Hoffman et al., 2008; Lieb, Becker and 
Altamura, 2005; Wittchen et al., 2000). 
 19 
Of the two generic instruments applied in the ANCORA study to measuring the health-
related quality of life, we decided to use EQ-5D because it enabled us to work with an 
index, to measure health status and to analyze the explicative variables. In the sample of 
GAD patients, the mean value of the health status index (EQindex) was ten points below that 
of the general population and of the control group. 
The EQ-5D data for the general population were taken from the Catalonian Health 
Survey (ECSA) for the years 2002 and 2006. This decision was taken because it was 
thus possible to obtain a much larger and more recent body of information than other 
indexes published in Spain, which enabled us to apply the model developed by Dolan 
(1996) with dummy variables, thus avoiding the problem of possible inconsistencies 
within the index values (Dolan and Kind, 1996). Badia et al. (1999) produced a Spanish 
version of EQ-5D, for which purpose they used a linear function with no dummy 
variables. This index has been applied in various economic evaluation studies (Ciudad 
et al., 2004; Prieto et al., 2004). 
The decision to use VAS data in a health status survey (ESCA, 2002 and 2006) requires 
some explanation: this data source raises the question of how data are selected in 
drawing up an index. In general, health status indexes are obtained by means of diverse 
preference-measurement techniques, normally based on procedures for choosing among 
health states, with or without uncertainty, using evaluations of hypothetical health 
states, and not the actual, present one, as is the case of EQ-5D. The use of the former 
techniques is justified when the aim is to obtain indexes to be used for economic 
assessment. The present index, however, is aimed at measuring health status and obtains 
a descriptive measure of health, in which VAS values are associated with the actual 
health states perceived by the interviewees themselves. 
This study uses regression models to obtain the EQ-5D health status index and also to 
analyze the explicative variables for the latter. When a priori information is available 
(the two ESCA sample periods employed), Bayesian statistics were applied. This 
technique incorporates a priori information in estimating the coefficients, which makes 
it possible to improve the estimates of the parameters and, from the a posteriori 
distributions of the coefficients, achieve targeted estimations and calculate Bayesian 
probability intervals (BI). 
The data on the costs of the illness are those obtained by the ANCORA study (Rovira et 
al., 2008). Both healthcare and non-healthcare direct costs are included, together with 
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the indirect costs of lost productivity due to sick leave. For the GAD patients, a poorer 
self-perceived health status and higher scores on the Hamilton scale were associated 
with higher costs, although in the latter case the explicative power of the model is weak. 
It is interesting to note that the GAD patients assign lower values to their health states than 
does the general population to the same health states. The GAD patients’ score on the VAS 
scale was four points lower than that given by the general population index. This finding 
was also obtained by the authors in a study of severe mental illness (Cabasés et al., 2005). 
This difference in perceptions might be important in terms of designing healthcare policies 
for diverse population groups. 
 
Conclusions 
Patients with GAD present a health-related quality of life that is clearly below that of the 
general population. In this respect, the present study recorded differences in health status 
of 10.24 points on the EQ-5D health status index. Both the patient’s age and a higher score 
on the Hamilton scale were negatively related to health variables. For the group of GAD 
patients, it was found that a poorer self-perceived health status and a higher score on the 
Hamilton scale were associated with higher costs provoked by the illness, although the 
explicative power of the model in the latter case is weak. Finally, the GAD patients assign 
lower values to their health states than does the general population to the same health 
states, with a VAS score four points lower than the value obtained by the health status 
index.  
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